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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder whose clinical manifestations
appear in old age. The sporadic nature of 90% of AD cases, the differential susceptibility and course
of illness, as well as the late age onset of the disease suggest that epigenetic and environmental
components play a role in the etiology of late onset AD (LOAD). Animal exposure studies
demonstrated that AD may begin early in life and may involve the interplay between the environment,
epigenetics and oxidative stress. Early life exposure of rodents and primates to the xenobiotic metal
lead (Pb) enhanced the expression of genes associated with AD, repressed the expression of others,
and increased the burden of oxidative DNA damage in the aged brain. Epigenetic mechanisms that
control gene expression and promote the accumulation of oxidative DNA damage are mediated
through alterations in the methylation or oxidation of CpG dinucleotides. We found that
environmental influences occurring during brain development inhibit DNA methyltransferases, thus
hypomethylating promoters of genes associated with AD such as the beta- amyloid precursor protein
(APP). This early life imprint was sustained and triggered later in life to increase the levels of APP
and amyloid-beta (Aβ). Increased Aβ levels promoted the production of reactive oxygen species
(ROS) which damage DNA and accelerate neurodegenerative events. While AD-associated genes
were over-expressed late in life, others were repressed, suggesting that these early life perturbations
result in hypomethylation as well as hypermethylation of genes. The hypermethylated genes are
rendered susceptible to Aβ-enhanced oxidative DNA damage because methylcytosines restrict repair
of adjacent hydroxyguanosines. While the conditions leading to early life hypo or hyper methylation
of specific genes are not known, these changes can impact gene expression and imprint susceptibility
to oxidative DNA damage in the aged brain.
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Introduction
Epigenetics is a major mechanism that accommodates gene-expression changes in response to
gene-environment interactions [1,2]. Epigenetics refers to modifications in gene expression
that are influenced by DNA methylation and/or chromatin structure, RNA editing and RNA
interference without any changes in DNA sequences [3]. DNA methylation and histone
deacetylation are known to occur shortly after DNA synthesis and could be modified by diverse
physiological or pathological factors altering gene expression for the lifetime of the organism.
Epigenetics and mental disorders
Despite that the bulk of the work in epigenetics has been developed in cancer research [4],
there is recognition of epigenetic aberrations in mental illnesses, namely in fragile X disease
and Retts syndrome [5–7]. Fragile X disease is associated with an expanded (>250 copies)
number of hypermethylated CGG repeats 5′ of the FMR1 gene that results in down regulation
of the gene [5,6]. Disease severity in Fragile X is directly correlated with the extent of
methylation in the 5′ region of the FMR1 gene [8]. Retts syndrome, on the other hand, is linked
to mutations in the gene encoding the methylated cytosine binding protein (MECP2) [7]. The
MECP2 recruits a variety of proteins that form a complex thus repressing gene expression
[9]. Both, Fragile X and Retts syndrome, are responses to well established alterations to a single
gene. However, recent work in autism spectrum disorders suggests a major epigenetic
component to the origin of the disease, indicating some contribution of differential methylation,
but not to a single gene [10].
DNA methylation is one of the most studied aspects of epigenetic modifications. The addition
or removal of methyl groups from cytosines can impact gene expression and alter cell and
organism function. For example, hypomethylation of the membrane-bound catechol-O-
methyltransferase (MB-COMT) gene has been implicated in both schizophrenia and bipolar
disorder [11]. On the other hand, hypermethylation of the RELN (reelin) gene has been shown
to be associated with schizophrenia [12]. In addition to DNA methylation, other mechanisms
linked to epigenetic regulation have been found to play a role in neuronal function, as
demonstrated by the use of inhibitors of histone deacetylases to ameliorate deficits in a wide
range of psychiatric and neurological conditions [13]. Recent research points to endogenous
systems, such as sirtuins, a group of nicotinamide (NAD+)-dependent deacetylases/ADP-
ribosyltransferases, playing a major role in the beneficial response to longevity extending
protocols such as caloric restriction [14]; however, whether their neuroprotective effects are
due to the deacetylase activity remains to be elucidated [15].
Genetics and epigentics of AD
Alzheimer’s disease (AD) is a gradual and irreversible, progressive neurodegenerative disorder
which results in dementia and death. AD pathology is characterized by senile plaques and
neurofibrillary tangles (NFTs), combined with massive neuronal loss, mainly in the
hippocampus and association regions of the neocortex. The major constituents of senile plaques
are 39–42 amino acid peptides, snipped from a larger protein called beta-amyloid precursor
protein (APP) [16–21]. Of these, the Amyloid-β (Aβ) form that is comprised of 42 amino acids
is considered the most amyloidogenic.
The majority of AD cases occur in the elderly; however, it is still unresolved whether AD is a
disease of old age or whether it has earlier beginnings. Epidemiological studies have shown
that people with dementia are more likely to have had low scores on intelligence tests when
they were children when compared to people without dementia [22]. These findings indicate
that AD patients may arrive at old age with significant predisposing deficits. Some studies
point to a possible role for epigenetic changes on AD etiology. AD patients are among the few
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that may display high homocysteine (HCY) and low B12 and folate in blood, suggesting a
dysregulation in the s-adenosylmethionine cycle required for epigenetic regulation through
DNA methylation. It is worth noting that expression of APP and beta-APP cleaving enzyme
(BACE) genes is regulated via methylation of their promoters [23].
Furthering the possibility for an epigenetic impact in AD, structural genomics studies have
demonstrated that more than 200 genes might be involved in AD pathogenesis [24]. In addition,
the AD population exhibits a higher absolute genetic variation rate of 40–60% and AD patients
differ in their genomic architecture from patients with other forms of dementia [24]. Between
5–10% of AD cases are of familial origin and involve mutations in genes associated with APP
biosynthesis and proteolytic processing [25–28]. The genetics of AD have revealed that early
(<60 years old) onset AD (EOAD) is associated with APP or the presenilins, while the risk to
develop late onset AD (LOAD) is linked to the apolipoprotein E (ApoE) polymorphism [29].
Genetics plays a major role in EOAD; however, LOAD which represents over 90% of cases
is sporadic in nature and remains with an unexplained etiology. Twin studies often used to
confirm the inheritance pattern of a disease have shown an estimated concordance well below
100% (20–80%) for AD, suggesting that LOAD is a complex non-Mendelian disease [30–
32]. Prefrontal cortex and lymphocytes from AD patients were used to analyze DNA
methylation patterns in genes with a potential role in AD etiology. An age-specific epigenetic
drift associated with unusual methylation patters in LOAD was identified, supporting a
potential role of epigenetic effects in the development of the disease [33]. Additionally, genes
that are genetically associated with LOAD (PSEN1, APOE) showed the largest inter-individual
variance in DNA methylation, with the APOE gene exhibiting the most variably methylated
sequences. APOE presented a bimodal methylation pattern, with a hypomethylated CpG-poor
promoter and a fully methylated 3′-CpG-island, containing the sequences for the ε4-haplotype,
the only established genetic risk factor for LOAD [33]. Interestingly, the gene MTHFR, coding
for methylenetetrahydrofolate reductase, showed a significant inter-individual epigenetic
variability. Alteration in MTHFR expression can influence homocystine levels, which may
contribute to LOAD predisposition [33]. The sporadic nature of the disease, the differential
susceptibility and course of illness in males and females, as well as the late age onset of the
disease add to the hypothesis that epigenetic and perhaps environmental components play a
role in the etiology of LOAD [33].
Role of oxidative stress in the etiology of AD
In addition to the established pathology of amyloid plaques and neurofibrillary tangles in the
brain of AD sufferers, there is a growing body of evidence indicating changes in the redox
status of AD brains. This is supported by findings of increased levels of oxidative damage
markers in every major cellular macromolecule (proteins, lipids, and DNA) [34]. Also,
alteration in the expression of antioxidant systems lends support to a role for free radical
damage in AD pathology [35]. Due to their postmitotic nature, damage to DNA in neurons
could be highly detrimental to their function and viability. Guanine (G) has the lowest oxidation
potential of the DNA bases; thus, 8-oxo-7,8-dihydro-2′-deoxyguanosine (oxo8dG) is the most
prevalent form of oxidative base modifications produced [36–38]. Some evidence suggests
that in addition to its mutagenic properties, presence of 8-oxodG in DNA can alter binding of
transcription factors and can impact epigenetic signaling [39,40].
Scope of the present review
This review focuses on epigenetics and explores the role of the environment in the promotion
of AD pathogenesis through transcriptional dysregulation of genes associated with AD. In
addition to the alteration in APP and Aβ metabolism, age-related accumulation of oxidative
damage is also suspected to play a role in the pathogenesis of AD. Thus, any environmental
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agent that significantly alters the redox potential of the aging brain can theoretically promote
AD pathology. Here we will explore the interactions between DNA methylation and DNA
oxidation and propose mechanisms that attempt to explain LOAD as a disease in which gene
expression is reprogrammed by early life events that alter the methylation profile of genes and
modify susceptibility to DNA damage thus resulting in neurodegeneration.
Exposure to Pb and the developmental-basis of AD
In a seminal study in 1989, David Barker and colleagues demonstrated an inverse relationship
between birth weight and the incidence of cardiovascular disease. The Barker hypothesis, also
known as the Fetal or “Developmental Basis of Adult Disease”, states that many adult diseases
might have a developmental origin [41–44]. A large body of subsequent clinical and
experimental data has supported this hypothesis and has shown that diseases of the
cardiovascular system, hypothalamic–pituitary–adrenal (HPA) axis, and diabetes can also be
affected by nutritional imbalances during pregnancy [45–47]. Some clinical and animal studies
suggest that certain deficiencies in the CNS in adults may also be rooted in alterations during
development. Memory impairment in adult animals and diseases such as schizophrenia have
been linked to infection, fetal malnutrition or hypoxia in early life [48–51]. In addition to
lending support for a developmental origin of disease, these observations serve to propose a
new concept regarding some adult diseases that emphasizes the role of environmental factors
acting in the periconceptual, embryonic, fetal, and infantile phases of life [52]. The impact of
such influences early in life maybe partially mediated through epigenetic mechanisms that
involve DNA methylation.
Given the recognized effects of Pb exposure in children, important work has been directed to
understand the consequences and the mechanisms linked to Pb exposure in this susceptible
population [53]. Pb is known to produce cognitive and behavioral deficits in children [54,55]
with the added risk of being ubiquitous in distribution. In relation to risks associated with Pb
exposure in adult populations, several population-based case-control studies have found that
chronic occupational exposure to Pb as well as other metals is associated with the incidence
of Parkinson’s disease [56]. Other studies point to a relation between high blood and bone Pb
levels and increased risk of Amyotrophic Lateral Sclerosis (ALS), suggesting that Pb exposure
plays a role in the etiology of the disease [57]. While these studies provided hints as to the
possible connection between Pb exposure and neurodegenerative disease, a seminal work
looked at tibia bone Pb levels in 529 former organo-lead workers and its relationship to ApoE
genotype, a known risk factor for AD. Results led to conclusion that the persistent CNS effects
of Pb are more toxic in individuals with at least one ApoE ε4 allele [58]. The link between past
adult Pb exposure and neurodegeneration was further established by the same research group
using brain MRI imaging [59] and was consistent with their previous work showing an
association between Pb exposure and longitudinal cognitive decline. While these studies
focused on adult occupational exposure to Pb, it is not known if the workers they studied had
been previously exposed to Pb as children.
Animal studies from our laboratories strongly suggest that exposure to Pb during development
can be a risk factor that promotes the pathogenesis of AD [60]. To examine latent responses
to developmental Pb exposure, we monitored the lifetime expression of the APP gene. We
observed that APP mRNA expression was transiently-induced in neonates, but exhibited a
delayed over-expression 20 months after exposure to Pb had ceased. This up-regulation in APP
mRNA expression was proportionate with a rise in activity of the transcription factor Sp1
(specificity protein 1), one of the regulators of the APP gene. Furthermore, the increase in APP
gene expression in old age was accompanied by an elevation in APP and its amyloidogenic
Aβ product. However, APP gene expression, Sp1 activity and APP and Aβ protein levels were
unresponsive to Pb exposure during old age.
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In order to link these molecular perturbations to pathological consequences associated with
AD, we acquired the brains of cynomolgus monkeys who have been similarly exposed to Pb
as infants in the 1980’s. Primates are among the few animal models that express amyloid
plaques and other pathological features that are absent in normal non-transgenic rodents.
Experiments in tissue derived from these primates demonstrate that the APP mRNA, APP, and
Aβ are elevated in old monkeys developmentally-exposed to Pb. Immunohistochemical
analysis of Aβ deposition shows that early exposure to Pb alters the distribution of intracellular
Aβ staining and plaques formation [61]. These data suggest that environmental influences
occurring during brain development pre-determined the expression and regulation of APP later
in life, potentially altering the course of amyloidogenesis [60].
Ample evidence has accumulated that oxidative damage to macromolecules such as DNA,
protein, and lipids, as well as, a down-regulation in antioxidant enzymes is associated with AD
[62–65]. Interestingly, we have found elevations in the oxidative DNA marker 8-oxo-dG in
older rats that had been developmentally exposed to Pb [66]. We also found a similar
accumulation in 8-oxo-dG in aged primates developmentally-exposed to Pb [61]. There are
alternative hypothesis to elucidate the origin of this latent buildup of oxidized DNA. Increases
in Aβ could lead to the generation of reactive oxygen species promoting the formation of 8-
oxo-dG; alternatively, epigenetic modulation in the methylation pattern of cytosines could
interfere with the repair or oxidation potential of adjacent oxidized guanines [67].
DNA methylation and the environment
The late onset responses to developmental exposure to Pb are probably unique to the nervous
system and few other tissues. Since cells in most tissues turn-over and proteins are in a continual
cycle of synthesis and degradation, the molecular targets that would store and transmit this
information would have to reside in the genome of terminally-differentiated cells or cells that
continually divide passing along their genetic makeup. Furthermore, for the damage to persist
on the structure of the DNA, the perturbation has to escape recognition by DNA repair enzymes.
DNA methylation of cytosines is a major epigenetic event that can influence the regulation of
gene expression and has been linked to the process of gene imprinting in mammals. Alterations
in 5-methylcytosine patterns on the promoters of genes are the first level of regulation of gene
expression in development, differentiation, carcinogenesis, and aging. The methylation of
cytosine can sometimes serve as a heritable code by the selective action of some methylases
that act on cytosine nucleotides in a CG sequence. Methylation occurring predominantly at this
symmetrical CG dinucleotide, due to the preferences of DNA methyltransferase for a hemi-
methylated substrate, maintains specific heritable patterns of methylation [68].
DNA methylation patterns are mainly established in utero, and it has been established that the
fetal environment may alter such patterns leading to sustainable changes in gene expression
that endure for a lifetime [69]. In terms of the brain, this environmentally-dependent
modulatory period may continue into postnatal development. Genome-wide demethylation
patterns are also observed shortly after fertilization and followed later by a new wave of
methylation of the CG sequences [70]. Thus, the process of methylation and demethylation
appears to be a controlled programmed event providing cells with a broad developmental
potential and a mechanism that widens the means to regulate the expression of genes and to
transmit information beyond the one stored in the genetic code.
Animal studies have clearly demonstrated that early-age environmental stimuli can alter
methylation patterns leading to gene expression changes which may result in modified
behaviors or increase disease risk in adulthood. It was shown that maternal grooming changed
the methylation pattern and expression of the glucocorticoid receptor in the hippocampus in
rat offspring, leading to permanent changes in their stress response [71]. In a different approach,
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it was shown that modification of the maternal diet through pregnancy led to a decrease in the
methylation of the glucocorticoid receptor (GR) and the peroxisomal proliferator-activated
receptor (PPAR) genes which was consistent with their elevated mRNA expression in the
offspring after weaning [72].
In addition to behavioral and nutritional imbalances, chemical exposure can also interfere with
the status of DNA methylation. One way in which environmental agents or occupational
exposure could interfere with DNA methylation is by disrupting the enzymes that conduct such
reactions. In vitro studies show that the addition of cadmium (Cd) to hepatic nuclear extracts
inhibited DNA-methyltransferase [73]. More recently, it was reported that subchronic exposure
to Cd inhibited DNA-methyltransferase activity in cultured cells, while chronic exposure
enhanced the activity of the DNA-methyltransferase. The Cd effect in DNA methyltransferase
translated into altered levels of methylation of DNA, suggesting that the action of Cd on DNA
methylation may be responsible for its carcinogenic properties [74]. Some studies suggest that
modifications in methylation patterns might be related to other epigenetic processes such as
histone modifications [75]. In addition to DNA-methylation, environmental agents could also
disrupt chromatin restructuring and produce long-term alterations in gene expression. Reports
that examined sperm chromatin structure in monkeys found alterations at environmentally-
relevant blood Pb levels and other studies have shown decreases in the level of protamine-
DNA interactions that may alter sperm chromatin condensation [76,77]. However, very few
studies have been conducted on DNA-methylation in the brain and none have examined the
potential of environmental agents to disturb this process.
Structure of the APP promoter and DNA Methylation
The GC content of the APP promoter is estimated to be 72%, and the rate of CpG dinucleotides
is five times that observed in other eukaryotic promoters indicating that its expression would
be subject to regulation by DNA-methylation [78–82]. The Sp1 consensus sequence, 5′
GGGCGGG (lower strand, 5′CCCGCCC) contains CG dinucleotides and is present in several
places on the APP promoter. Few studies have examined methylcytosine levels on the APP
promoter and the published work provides a varied picture depending on the region of the
promoter that was examined. An analysis of CpG elements in the APP promoter region between
−460 and −275 did not detect methylation of cytosines in healthy human brain tissue [83]. On
the other hand, it was found that regions of the human and primate APP promoter upstream of
−500 displayed tissue and brain region-specific profiles of methylation, which crudely reflect
APP expression patterns [84]. More recently, it was established that there are at least 13
potential methylation sites in the region −236 to −101 of the human APP promoter [85,86].
Twenty-six percent of these cytosines were more frequently methylated in healthy individuals
between the ages of 35–70 years old, as compared to 8% in those aged 74–90 years of age.
This age–related reduction in methylcytosine was more prominent (ten-fold reduction) in some
locations (−207 to −182) of the APP promoter that belong to 9- and 11-bp-long GC-rich
elements, which are typical Sp1 DNA-binding sites [85]. Furthermore, these investigators
suggested that age-related demethylation of cytosines may have some significance in the Aβ
deposition in the aged brain [85]. Interestingly, BACE (beta-secretase), as well as PS1, are also
regulated by methylation, translating into changes of Aβ levels [87].
It is plausible that developmental exposure to Pb could exacerbate the demethylation process
of the APP promoter in old age thus elevating APP expression. Studies have shown that Sp1
DNA-binding is inhibited by methylation of cytosine in proximity to CpG sites in the consensus
sequence [88,89]. The expression of Sp1 target genes such as the epithelial gene T1a and MAO
B have also been shown to be regulated by increased methylation of CpG sites on or around
Sp1 DNA-binding sites [90–92].
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DNA methylation and oxidative stress
In CpG dinucleotides, the cytosine is the preferred base for DNA methylation, while the
guanine is the site for oxidative damage. 8-oxo-dG is widely used as biomarker of oxidative
DNA damage. In the absence of exogenous DNA-damaging reagents, endogenously formed
metabolic reactive oxygen species (ROS) are able to create 105 molecules of 8-oxo-dG in the
cells per day [93]. Oxidative DNA damage is primarily repaired by the base excision pathway
and base excision repair is initiated by a DNA glycosylase that recognizes the modified base
[94]. Oxoguanosine DNA glycosylase 1 (OGG1) is the major repair enzyme to recognize and
remove 8-oxo-dG. Oxidative DNA damage and possible deficiencies in Ogg1 are considered
to be a central factor in the process of aging and aging-related diseases such as Alzheimer’s
disease [95,96].
Our study has shown that developmental Pb exposure increases Aβ levels as well as 8-oxo-dG
production in old age [66]. Aβ is known to induce functional disturbances in vivo through its
pro-oxidant and neurotoxic properties [97,98]. Aβ promotes the formation of reactive oxygen
species (ROS) and the use of antioxidant can prevent Aβ elicited neurotoxic cascades [99–
102].
Few studies have addressed DNA methylation and DNA oxidative damage simultaneously as
an epigenetic phenomenon, and little is known on how DNA methylation and DNA oxidation
interact with each other. Researchers using synthetic DNA oligonucleotides have found
oxidation of guanine in CpG dinucleotide reduced the MBD (methyl group binding domain)
binding to that site [40]. When 5-methylcytosine is oxidized to 5-hydroxymethylcytosine, its
affinity to MBD is greatly reduced to the same level as unmethylated cytosine. Likewise, 8-
oxo-dG inhibits adjacent cytosine methylation [103,104]. Methylated CpG has also been found
to account for decreased transcription factor binding to the promoter region [89,91].
Given evidence that methylation regulates gene expression, results from our Pb exposure
studies suggest the occurrence of both hypomethylation and hypermethylation of genes. mRNA
levels of a series of transcription factors (TFs) were screened on postnatal day 5. This short
term exposure to Pb resulted in changes in the signal-dependent TFs such as the steroid receptor
superfamily (GR, ER, PR, RXRs, RARs, etc.), and development-specific factors (Sp1) [60].
The expression levels of some these TFs such as Sp1 were elevated, while the steroid receptor
super family exhibited a down regulation trend. Microarray array analysis of about 588
neurobiology-related human genes was also conducted to identify the genes that are altered
due to infantile exposure to Pb in the frontal association cortex of 23-year old cynomolgus
monkeys (unpublished data). The results showed that the expression profile of only a few genes
(22) was changed due to early life exposure to Pb. Most of the altered genes belonged to
neurotransmitter, growth receptors and signal transduction pathways. Searches were conducted
on various databases (Ensembl and NCBI nucleotides) to determine if the regulatory regions
of these genes were rich in CpG dinucleotides (>60%). We found all of the altered genes (with
the exception of two) were abundant in CpG dinucleotides in their 5′ untranslated regions (5′
UTR). About a third of these genes were elevated, while a majority were repressed.
These findings and published results on AD-related genes [60,61] demonstrate that early life
exposure to Pb may enhance the expression of some genes and depress the expression of others
([58]; unpublished studies). Although the direction of change in gene expression was opposite,
the modified genes have one thing in common, and that is abundance in CpG dinucleotides in
their promoter regions. It is thus clear that exposure to Pb can interfere with regulation of gene
expression by hypomethylating certain genes and hypermethylating others. Alteration in the
methylation patterns of genes can become permanent and carry with them built in susceptibility
to neurodegenerative events.
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Sustainable hypomethylation of the APP promoter for example can increase the ceiling of
expression of the APP gene in response to aging processes driving overproduction of APP and
Aβ levels. The increased Aβ levels then facilitate ROS production with their pro-oxidant
properties, damaging the DNA. Therefore, in cases of hypomethylation, DNA damage is
increased from the products of over expressed pro-oxidant genes. On the other hand,
hypermethylation early in life would render detrimental effects on both gene transcription and
repair pathways.
To model the interactions between methylation and oxidation, we synthesized oligonucleotides
that resembled the binding site for the transcription factor Sp1. In some oligos the cytosine in
a CpG was replaced by methylcytosine and the guanine by an 8-oxo-dG. A third oligo
containing both methylcytosine and 8-oxo-dG adjacent to each other was also prepared. We
then conducted DNA-binding and repair studies. Expectedly, we found that presence of either
5-methylctosine or 8-oxo-dG dramatically suppressed Sp1 DNA-binding; however the
combination of both had an effect greater than either alone (Figure 1A). Likewise, the repair
of 8-oxo-dG was greatly diminished when the 8-oxo-dG was preceded by 5-methylcytosine
(Figure 1B). These experiments show that the methylation status of a gene can greatly impact
gene expression and DNA repair. If a gene is methylated in a regulatory region during
development and faces subsequent oxidative stress in this same area, it will be greatly repressed.
Likewise, such a gene will be inadequately repaired. On the other hand, oxidized DNA will
inhibit DNA methylation of an adjacent cytosine [103,104].
While substitutions in synthetic DNA oligonucleotides show the interplay between oxidative
damage and methylation of DNA, this relationship can also be seen in cells. Studies with
oxidant-transformed cell lines have shown unusual changes of methylation patterns of several
genes. This suggests the oxidative DNA damage and DNA methylation interact with each other,
which may consequently alter the methylation patterns and transcriptional activity of affected
genes. In the case of the APP gene, oxidative and methylating changes in its promoter regions
can determine its expression as well as the levels of its gene products and their derivatives
associated with amyloid formation. Both hypermethylation and hypomethylation can be
impacted by environmental factors and the diet, as is oxidative stress. Through the methylation
pathway, supplementation with apple juice has been shown to attenuate presenilin-1
overexpression during dietary and genetically-induced oxidative stress [105]. Indeed, fruit and
vegetables juices play a beneficial role in potentially delaying the onset of Alzheimer’s disease
[106].
In considering methylation and oxidation, it is important to make some important distinctions.
Oxidation is a dynamic process that can occur at any time there is oxidative stress but is
typically high early and late in life, because high metabolic rate in the former and reduced
antioxidant defenses in the later. Furthermore, these observations are based on our published
work which profiled oxidative stress across the lifespan. We found that periods of early and
late life are times in which ROS levels are high as well the molecular targets for them. [66].
Methylation on the other hand is poorly understood and is presumed to occur during early
development and sustained for the rest of life. While there are DNA methylating enzymes, the
existence of a demethylating enzyme in mammalian systems remains controversial, and
actually it has been suggested that DNA repair enzymes could function a DNA demethylation
role [107,108]. Despite the known fact that methyl group donors available in the diet can alter
the methylation pattern in favor of hypermethylation, the natural mechanisms that underlie
hypomethylation are not fully understood. Furthermore, it is important to recognize that even
if a substance is not a pro-oxidant, it can still lead to an accumulation of oxidative damage
through alterations in methylation patterns that impact the repair of adjacent oxidized guanines.
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In our model, environmental agents such as heavy metals can inhibit the enzymes that maintain
or methylate DNA. In this scenario, the exposure to such metals has to occur during a
developmental period when such methylation patterns are being established; however, while
it is assumed that methylation patterns are maintained for life, it is also plausible that they are
dynamically changing. To evaluate this possibility, we quantified the content of methylcytosine
on three positions of the APP promoter in the frontal cortex of monkeys that were 6, 12, and
23 years old. We found that they all maintained their methylcytosine content, with the exception
of one position which decreased with age (Figure 2). Although this experiment examined only
a few sites out of possibly thousands, it suggests that both stable methylcytosine patterns and
alternating content are possible; however, how such selective effects are imparted is still
unknown. In terms of its relevance in human setting, larger–scale work on human subjects
supports our hypothesis by having shown that DNA methylation is altered over time in
individual humans in both genomic DNA as a whole and in specific, selected gene sequences
[109].
Conclusion
The Pb exposure model was used to test the hypothesis that the origins of AD begin early in
life and that environmental exposure can determine future disease susceptibility. The effects
of the original exposure would remain latent until an additional trigger or triggers affect the
exposed organism. Such a model operates through the regulatory sequences of a gene and
places the epigenotype center–stage over genotype in development of neuropsychiatric
disorders. We refer to the model as a ‘Latent Early–life Associated Regulation’ (LEARn) model
[66,110]. This model is not restricted to Pb and can be applied to nutritional deficiencies, stress,
chemical exposure or any other perturbation that interferes in the epigenetic programming of
gene expression. In summary our model proposes that interference by Pb early in life has a
dual effect on methylation of genes in terminally differentiated neurons. Genes whose
promoters are hypomethylated such as the APP gene are programmed to over-express
themselves in the face of a later, secondary trigger. On the other hand, genes that are
hypermethylated are destined for repression. In the context of AD pathogenesis, we
hypothesize that normal aging triggers induce pathogenically high APP gene expression in
exposed, hypomethylated APP, individuals, which in turn produces more APP, which is further
cleaved to build up Aβ levels. Large–scale age–related change in gene expression levels has
been previously documented in human brains [111]. The buildup in Aβ has multiple
consequences. It can produce disruption of synaptic function as a diffusible ligand; it can
aggregate to form plaques, or it can promote ROS production. ROS can in turn damage DNA
and thus genes which had been previously hypermethylated will have a reduced capacity to
defend and repair against this ROS onslaught because of structural alteration on CpG
dinucleotides. The reduced capacity to repair DNA and the transcriptional enhancement in
Aβ production converge to exact greater damage on neurons and result in cell loss. This is a
hypothetical model of how early events can build in susceptibility to disease later in life via
an interaction between exposure, epigenetics, and oxidative stress. Figure 3 describes the
proposed model of epigenetic changes and increased susceptibility to 8-oxo-dG accumulation
seen after developmental Pb exposure and in AD.
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Figure 1. Structural modifications in CpG dinucleotides and their impact on Sp1-binding and DNA
Repair
Sp1 binding and DNA repair glycosylase (Ogg1) activities were evaluated in oligonucleotides
containing a 5-methyl cytosine and/or an adjacent 8-oxo-dG. An unmodified oligonucleotide
was used as control. Top panels illustrate results for assessments of Sp1 binding (A) or Ogg1
activity (B); bottom panels illustrate the biological consequences of these modifications. A)
Sp1 binding was reduced by methylation or by presence of an oxidized G. However, the
inhibition was larger when both base modifications were present in the same sequence. B)
Similarly, presence of a methylated cytosine next to an oxidized G reduced the activity of
Ogg1, preventing repair of oxidative damage to DNA. The solid line represents time-associated
repair when only 8-oxo-dG is present; while, the dashed line represents repair when 5-mC is
adjacent to the oxidized G. Methods for Sp1 binding and Ogg1 activity have previously been
published [60,66]. The values presented were derived from 3–4 experiments.
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Figure 2. DNA methylation of the APP promoter across the lifespan
Pyrosequencing was used in order to quantify the methylation levels at different CpG sites of
the APP promoter. The methylation levels of the CpG dinucleotides located in the illustrated
region were quantified after bisulfite conversion. The graph shows changes in methylcytosine
content in these three different sites at different ages in the frontal cortex of monkeys. Three
monkeys per age group were used for this sequencing.
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Figure 3. Epigenetic modifications during development and their impact on gene expression, DNA
damage and neurodegeneration in the aging brain
It is presumed that DNA methylation during development sets the level of responsiveness of
a gene for life. The higher the methylation burden, the more silenced a gene is. Exposure to
Pb (or other perturbations) during development may inhibit DNA methylation of target genes
such as APP. The inhibition of DNA methylation patterns resets the responsiveness of the APP
promoter and the expression of the APP gene to a higher ceiling. The reset gene is over-
expressed when challenged by an aging trigger. This leads to an increase in the production of
APP and its amyloidogenic Aβ cleavage. Aβ forms aggregates and generates free radicals
which attack macromolecules such as DNA. Exposure to Pb (or other perturbation) early in
life may also enhance the methylation of some genes. The epigenetically modified genes may
be more susceptible to oxidative stress later in life. Epigenetic modulations of 5-methylcytosine
residues impair the capacity to repair adjacent oxidized guanine bases thereby rendering
neurons more susceptible to damage. The increase in the levels of Aβ promotes aggregation,
free radical formation, and DNA damage. These events enhance neurodegeneration and the
formation of senile plaques in the aging brain.
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